Loading...
Market
Novo Nordisk's response to U.S. Senate HELP Committee by September 30, 2024
5
Resolution / Starting Odds
Detailed explanation provided • 33%
Partial explanation provided • 33%
No explanation provided • 33%
Official documents or public announcements from Novo Nordisk or the U.S. Senate HELP Committee
Story
U.S. Senate Panel to Vote on June 18 on Subpoena for Novo Nordisk Over Ozempic, Wegovy Prices
Jun 11, 2024, 03:00 PM
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, chaired by Senator Bernie Sanders, announced it will vote on June 18 to decide whether to subpoena Doug Langa, President of Novo Nordisk Inc. This action is prompted by the significant price disparity for weight loss drugs Ozempic and Wegovy between the U.S. and other countries. Americans are charged $969 for Ozempic, while Germans pay only $59. The committee seeks an explanation for why these drugs cost up to 10 to 15 times more in the U.S. compared to other nations. Novo Nordisk has not yet provided a satisfactory response to these inquiries. The vote will take place later this month.
View original story
Similar markets
Profit decline over 20% • 25%
Profit decline 10-20% • 25%
Profit decline less than 10% • 25%
No significant change or profit increase • 25%
Stock price increases by more than 20% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by less than 10% • 25%
Stock price decreases • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Cease imports of affected parts • 33%
Defend current practices • 33%
Announce internal investigation • 33%
Yes • 50%
No • 50%
No action taken • 25%
Sanctions imposed • 25%
Fines imposed • 25%
Supply chain overhaul mandated • 25%
Deny any wrongdoing • 25%
Admit partial wrongdoing • 25%
Settle without admission of wrongdoing • 25%
No response • 25%
<$5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
>$15 billion • 25%
No significant action • 33%
Policy changes • 33%
Personnel changes • 33%